Breaking News
RSS Feed

Urgent Message Regarding Exposure to Du Pont C-8

Since the early 1950’s, Du Pont has used C-8, a hazardous substance, in the operations at its Plant. Aware of the potential toxicity of the chemical when released into the environment, Du Pont discovered over the next several decades that C-8 was in the blood of individuals all over the country. The highest levels of penetration were found in people in Ohio and West Virginia that live and work close to the Du Pont plant. Additionally, Du Pont knew C-8 exposure caused severe health problems, such as cancer, and never reported the dangers of C-8 to the public or the government. Even worse, Du Pont continues its use of C-8 to prevent loss of its profits. Douglas & London actively represents people seeking recovery against Du Pont for personal injuries caused by the release of harmful levels of C-8 into the environment and, as a result, into the air and drinking water of the area surrounding its Washington Works Plant in Wood County, WV.

Click here to read more.

Bayer Combination Aspirin Multidistrict Litigation

A proposed Bayer combination Aspirin settlement has been reached in the Bayer Combination Aspirin Multidistrict Litigation, of which firm partner, Michael London, serves as Co-Lead and Liaison Counsel.     The $15 million settlement, which has been preliminarily approved by the Court, would provide funds for consumers who purchased Bayer Aspirin with Heart Advantage between Jan. 1, 2008 and July 23, 2012, and consumers who purchased Bayer Women’s Low-Dose Aspirin + Calcium between Jan. 1, 2000 and July 23, 2012.

A notice with the rights and responsibilities of class members is available here. If you are a member of the class, you may fill out this claim form to make a claim for payment from the settlement fund.

The settlement is not yet final and must be approved by the court before settlement funds can be distributed to class members. More information about this settlement is available at http://www.bayercombinationaspirinsettlement.com/

As way of brief background, in November 2008 Douglas & London P.C. filed a class action complaint against Bayer Healthcare arising out of its alleged unlawful marketing of two combination aspirin products:  Bayer Aspirin with Heart Advantage and Bayer Women’s Low Dose Aspirin + Calcium.   Specifically, it was alleged that the two products were sold by Bayer Healthcare without approval by the Food and Drug Administration and without proof that the two products were safe and effective as advertised.   In April 2009, this action and others were consolidated in the United States District Court for the Eastern District of New York before the Honorable Judge Brian M. Cogan.    Thereafter, a Master Complaint was filed on behalf of all plaintiffs.    Following two years of extensive discovery and motion practice, the proposed settlement was reached.

Urgent Message For Pradaxa Users

Firm partner, Michael A. London, was appointed as co-lead counsel by the federal judge overseeing all of the federal court lawsuits alleging injuries from the drug Pradaxa. Pradaxa (dabigatran) is a drug often prescribed to prevent strokes and assist in reducing the risk of blood clots frequently associated with atrial fibrillation.  Its side effects include internal bleeding, ulcers and hemorrhaging. To date, there have been about 260 deaths related to Pradaxa use worldwide. If you or a loved one has taken Pradaxa and has experienced any of these side effects, you may be entitled to a large monetary award. Contact our personal injury law firm today for more information.

Breaking News – Actos Users

Douglas & London, P.C., is representing individuals diagnosed with bladder cancer after taking Actos. You may be entitled to compensation from the manufacturer for your injuries. For your free legal consultation fill out our online contact form.

The United States Food and Drug Administration have issued a warning about the diabetes drug pioglitazone, marketed as Actos. This information is based on the FDA’s review of data from a planned five-year interim analysis of an ongoing ten-year study.

Actos is an oral diabetes medicine that has been shown by recent studies to lead to serious injuries such as an increased risk of bladder cancer. Pioglitazone, the chemical name for Actos was sold under the trade names Actos, ActoplusMet, Competact and Duetact. For your free legal consultation fill out our online Contact Form.


Papaya Salmonella Victims Increase to 141 with More Possible

17 August 2017 @ 5:58 am

As of August 11, 2017, the Centers for Disease Control (CDC) is reporting that 141 people in nineteen states have confirmed cases of strains of salmonella traced back to papayas imported from Mexic ...

Increased Risk of Bone Fractures with Invokana and Invokamet XR

15 August 2017 @ 5:17 am

Despite a multitude of warnings for a drug taken for treatment of type 2 diabetes, the U.S. Food and Drug Administration (FDA) has expanded indications for Invokamet (canagliflozin and metformin). ...

Endo Agrees to Additional $775M Settlement for a Total of $2.6B

12 August 2017 @ 6:55 pm

As of August 7, 2017, Endo International has agreed to set aside an additional $775 million to resolve the company’s remaining mesh lawsuits’ allegations related to the Transvaginal Mesh (TVM) ...

General Motors Recalls 800,000 Trucks due to Power Steering Defects

12 August 2017 @ 6:49 pm

Nearly 800,000 pickup trucks are being recalled by General Motors because they may suddenly lose power steering while the truck is being driven, and the sudden steering jolt may cause drivers to lo ...

Mixed Metals are Focus of Stryker LFIT V40 Hip Implant Litigation

8 August 2017 @ 2:10 am

The Stryker Corporation is facing parallel litigations in Boston and New Jersey defending its LFIT Anatomic CoCr V40 Femoral Head (Cobalt Chromium V40) with allegations that the metal-on-metal ball ...